| name | icsm-offer-tt-after-radiation-low-psa-consent |
| description | This skill guides offering testosterone therapy after radiation or brachytherapy when a patient's PSA has fallen to a low level, typically at 3-6 months post-treatment. It is triggered when clinicians consider initiating testosterone and seek confirmation that the PSA is sufficiently low, accompanied by a consent form discussing uncertainties. |
Offer testosterone therapy after radiation/brachytherapy once PSA is low (typically 3-6 months) with consent
STEP 1 — Gather Information
Collect history of prostate cancer treated with external beam radiation or brachytherapy, baseline and current PSA values, time since treatment, total testosterone level, symptoms of hypogonadism, hematocrit, and patient goals. If PSA is not low (e.g., >0.1 ng/mL) or less than 3 months have passed since treatment, defer testosterone consideration and continue monitoring; otherwise proceed to Step 2.
STEP 2 — Rule In / Rule Out
Is the PSA low (e.g., ≤0.1 ng/mL or undetectable per assay) and at least 3 months post-radiation/brachytherapy? If yes, rule in and proceed to Step 3; if no, rule out and defer testosterone therapy, recommending repeat PSA in 1-3 months.
STEP 3 — Classify or Stratify
Stratify prostate cancer risk based on pretreatment Gleason score, stage, and PSA: low-risk (Gleason ≤6, T1-T2a, PSA <10 ng/mL) vs intermediate/high-risk. If low-risk, proceed to Step 4; if intermediate/high-risk, obtain multidisciplinary oncology/urology review before considering testosterone therapy.
STEP 4 — Decide
For low-risk patients meeting criteria, offer testosterone therapy after shared decision-making, providing a consent form that discusses uncertainties regarding long-term prostate cancer safety, and initiate therapy aiming for mid-normal testosterone range with baseline labs and follow-up per monitoring schedule.
Clinical Guardrails / Mimics / Pitfalls
Do not offer testosterone if PSA is rising or detectable above assay limit; do not omit the consent discussion about uncertainties; do not initiate in men with hematocrit ≥54% without evaluation; do not use in high-risk prostate cancer without multidisciplinary review; avoid in men with active or suspected prostate cancer progression.
Concrete Clinical Example
A 68-year-old man completed external beam radiotherapy for Gleason 3+3 prostate cancer 5 months ago. His PSA is 0.02 ng/mL (down from 4.1 pre-treatment). He reports low libido and fatigue, with total testosterone 8.2 nmol/L. Hematocrit is 48%. After confirming low PSA and adequate time, low-risk classification is made. He receives a consent form discussing potential risks and benefits, and testosterone gel is initiated with follow-up labs in 3 months.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036
